Assessment of the effects of inhibition or induction of CYP2C19 and CYP2C9 enzymes, or inhibition of OAT3, on the pharmacokinetics of abrocitinib and its …
X Wang, ME Dowty, A Wouters, S Tatulych… - European journal of …, 2022 - Springer
Abstract Background and Objective Abrocitinib is a Janus kinase 1-selective inhibitor for the
treatment of moderate-to-severe atopic dermatitis. Abrocitinib is eliminated primarily by …
treatment of moderate-to-severe atopic dermatitis. Abrocitinib is eliminated primarily by …